First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Article Urology & Nephrology

Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model

Austin N. Kirschner et al.

Summary: Intravesical administration of anti-PD-1 is a promising treatment route for localized bladder cancer, with comparable overall survival to systemic anti-PD-1 in this mouse model. Intravesical anti-PD-1 increases CD8+ T cells in treated tumors and long-term immunity was seen to tumor rechallenge.

JOURNAL OF UROLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Spatially organized multicellular immune hubs in human colorectal cancer

Karin Pelka et al.

Summary: By analyzing the transcriptional profiles of cells in tumors, differences in immune responses between mismatch repair-deficient (MMRd) and mismatch repair-proficient (MMRp) tumors were identified, as well as the logic behind the interaction of malignant and immune cells discovered within tumors.

CELL (2021)

Add to Collection

Article Oncology

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Balar et al.

Summary: This study evaluated the efficacy and safety of pembrolizumab, a PD-1 inhibitor, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. The results showed that pembrolizumab monotherapy was well-tolerated and demonstrated promising antitumor activity in this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Review Andrology